The Phase 1b trial will evaluate the combination in patients with muscle invasive bladder cancer (MIBC) who are scheduled for radical cystectomy. Few options are available to treat MIBC, which may metastasize and often leads to death.
In conjunction with this collaboration, Bristol-Myers Squibb has made an equity investment in Taris.
The Taris System, deployed and retrieved using minimally-invasive, in-office procedures, is designed to continuously release drugs in the bladder over weeks to months.
TAR-200, the company's lead investigational program in bladder cancer, is designed to release the chemotherapeutic agent gemcitabine continuously in the bladder over seven days.
Taris Biomedical is building a therapeutically-focused urology company, developing targeted new therapies for millions of patients suffering from difficult-to-treat bladder diseases. The company is advancing therapies for debilitating conditions, including bladder cancer and overactive bladder, enabled by continuous local dosing.
Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression. Opdivo's leading global development program includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has enrolled more than 25,000 patients.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesised drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV).
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results